About applied therapeutics inc - APLT
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
APLT At a Glance
Applied Therapeutics, Inc.
545 5th Avenue
New York, New York 10017
| Phone | 1-212-220-9226 | Revenue | 455.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -105,624,000.00 | |
| Sector | Health Technology | Employees | 35 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
APLT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 262.571 |
| Price to Book Ratio | 2.061 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.413 |
| Enterprise Value to Sales | 94.212 |
| Total Debt to Enterprise Value | 0.065 |
APLT Efficiency
| Revenue/Employee | 13,000.00 |
| Income Per Employee | -3,017,828.571 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.006 |
APLT Liquidity
| Current Ratio | 3.064 |
| Quick Ratio | 3.064 |
| Cash Ratio | 2.909 |
APLT Profitability
| Gross Margin | 6.593 |
| Operating Margin | -22,922.857 |
| Pretax Margin | -23,214.066 |
| Net Margin | -23,214.066 |
| Return on Assets | -149.267 |
| Return on Equity | -529.975 |
| Return on Total Capital | -176.626 |
| Return on Invested Capital | -499.558 |
APLT Capital Structure
| Total Debt to Total Equity | 4.903 |
| Total Debt to Total Capital | 4.674 |
| Total Debt to Total Assets | 3.224 |
| Long-Term Debt to Equity | 4.191 |
| Long-Term Debt to Total Capital | 3.995 |